#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Wendy Chang Email
Sr VP, Human Resources . Harpoon Therapeutics
South San Francisco, CA
LocationPrimary Email
How to contact Wendy Chang
Join and see Wendy's contact info for free!Current Roles
Employees:
63Revenue:
$26.8MAbout
Harpoon Therapeutics is a clinical stage biotechnology company co-founded by Patrick Bauerle, a pioneer in T-cell engagement, and Luke Evnin (MPM Capital) in 2015 to develop and commercialize a novel class of T cell recruiting antibodies engage a patient's own immune cells to fight cancer and other diseases. The world-class team of protein engineers and immunologists at Harpoon have built upon the successful development of the bispecific (BiTE or bispecific T cell engager) antibody Blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. Harpoon's tri-specific T-cell redirection platform -- TriTAC -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, CAR-T and other T-cell engaging approaches by improving activity against solid tumors convenience of administration treatment of more tumor types and other immunologic diseases. Harpoon has discovered proprietary drug candidates and has an expansive research portfolio leveraging the TriTAC platform. Harpoon plans to file its first 2 INDs and initiate its first clinical study in 2018. Harpoon Therapeutics recently completed a Series B financing round with investors: MPM Capital, New Leaf Venture Partners, Arix Biosciences, and Taiho Ventures.Harpoon Therapeutics Address
611 Gateway Blvd.South San Francisco, CA
United States